论文部分内容阅读
目的:评价麝香保心丸对急性冠脉综合征(ACS)患者氯吡格雷抵抗(CR)的影响。方法:选择氯吡格雷抵抗患者64例,将其随机分为两组。A组34例,口服氯吡格雷75mg,同时加用麝香保心丸4粒/次,每日3次。B组30例,每日口服氯吡格雷75mg。C组为无氯吡格雷抵抗患者35例,每日口服氯吡格雷75mg。于服氯吡格雷前、服药后2周分别测定血小板聚集率抑制率。结果:3组患者在服用氯吡格雷前血小板聚集率无统计学意义(P>0.05),服药1周后,血小板聚集率A组为(21.5±3.9)%,B组为(28.1±5.7)%,C组为(17.9±4.7)%;血小板抑制率A组为(10.2±2.5)%,B组为(8.8±1.8)%,C组为(14.6±2.3),与治疗前比较有统计学意义(P<0.05)。其中,血小板聚集率C组A组>B组(P<0.05)。结论:麝香保心丸可以降低ACS患者发生氯吡格雷抵抗的几率。
Objective: To evaluate the effect of Shexiang Baoxin Pill on clopidogrel resistance (CR) in patients with acute coronary syndrome (ACS). Methods: Sixty-four patients with clopidogrel resistance were selected and randomly divided into two groups. A group of 34 patients, oral clopidogrel 75mg, while adding musk pill 4 / time, 3 times a day. Group B 30 cases, daily oral clopidogrel 75mg. Group C was clopidogrel-free patients with 35 patients, daily oral clopidogrel 75mg. Before taking clopidogrel, the inhibition rate of platelet aggregation was measured 2 weeks after taking the medicine. Results: After 3 weeks of taking clopidogrel, platelet aggregation rate was (21.5 ± 3.9)% in group A and (28.1 ± 5.7) in group B % In group C and (17.9 ± 4.7)% in group C, respectively. The rate of platelet inhibition was (10.2 ± 2.5)% in group A, (8.8 ± 1.8)% in group B and (14.6 ± 2.3) in group C Significance (P <0.05). Among them, platelet aggregation rate in group C group A> group B (P <0.05). Conclusion: Shexiang Baoxin Pill can reduce the incidence of clopidogrel resistance in ACS patients.